New shot shows promise for Hard-to-Treat cancers

NCT ID NCT03667170

Recruiting now Disease control Sponsor: 3D Medicines (Sichuan) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing an immunotherapy drug called KN035, given as a shot under the skin, for people with advanced solid tumors that have specific genetic features (dMMR or MSI-H). The study includes 200 participants with colorectal cancer or other solid tumors who have already tried standard treatments. The main goal is to see if the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KN035 (a type of immunotherapy given as a shot under the skin)
What this could lead to: If successful, this could offer a new treatment option for people with certain hard-to-treat cancers that have specific genetic features.
What could go wrong: This is a mid-stage trial with only 200 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects like immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal carcinoma colorectal neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Peking University Cancer Hospital, Peking University
RECRUITING

Beijing, Beijing Municipality, 100010, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.